Child/Adolescent Anxiety Multimodal Study (CAMS): Rationale, design, and methods

Child and Adolescent Psychiatry and Mental Health

Volumn 4, Issue , 2010, Pages

  Compton, Scott N ^a   Walkup, John T ^b   Albano, Anne Marie ^c   Piacentini, John C ^d   Birmaher, Boris ^e   Sherrill, Joel T ^f   Ginsburg, Golda S ^b   Rynn, Moira A ^c   McCracken, James T ^d   Waslick, Bruce D ^g   Iyengar, Satish ^e   Kendall, Phillip C ^h   March, John S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

^c NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

^f NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^g BAYSTATE MEDICAL CENTER   (United States)

^h TEMPLE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUVOXAMINE; PLACEBO; SERTRALINE;

ANXIETY DISORDER; CHILD PSYCHIATRY; CHILD/ADOLESCENT ANXIETY MULTIMODAL STUDY; CLINICAL PROTOCOL; CLINICAL TRIAL; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOCTOR PATIENT RELATION; ENGLISH AS A SECOND LANGUAGE; ETHNICITY; FUNCTIONAL ASSESSMENT; GENERALIZED ANXIETY DISORDER; HEALTH CARE QUALITY; HEALTH CARE UTILIZATION; HUMAN; MEDICAL DECISION MAKING; MONOTHERAPY; PATIENT SAFETY; PATIENT SATISFACTION; PEDIATRICS; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; PSYCHOSOCIAL CARE; REVIEW; SEPARATION ANXIETY DISORDER; SOCIAL PHOBIA; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 76749146022     PISSN: None     EISSN: 17532000     Source Type: Journal    
DOI: 10.1186/1753-2000-4-1     Document Type: Review

References (50)

1. Costello EJ, Egger HL, Angold A. The Developmental Epidemiology of Anxiety Disorders: Phenomenology, Prevalence, and Comorbidity. Child and Adolescent Psychiatric Clinics of North America 2005, 14:631-648. 10.1016/j.chc.2005.06.003, 16171696.
2. Ezpeleta L, Keeler G, Erkanli A, Costello EJ, Angold A. Epidemiology of psychiatric disability in childhood and adolescence. Journal of Child Psychology & Psychiatry & Allied Disciplines 2001, 42:901-914.
3. Kessler RC, Berglund P, Demler O, Jin R, Walters EE. Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry 2005, 62:593-602. 10.1001/archpsyc.62.6.593, 15939837.
4. Wittchen H-U, Stein M, Kessler R. Social fears and social phobia in a community sample of adolescents and young adults: Prevalence, risk factors and co-morbidity. Psychological Medicine 1999, 29:309-323. 10.1017/S0033291798008174, 10218923.
5. Albano AM, Chorpita BF, Barlow DH. Childhood anxiety disorders. Child psychopathology 2003, 279-329. New York, NY: Guilford Press, 2.
6. Kendall PC, Brady EU. Comorbidity in the anxiety disorders of childhood: Implications for validity and clinical significance. Anxiety and depression in adults and children Banff international behavioral science series 1995, 3-36. Thousand Oaks, CA: Sage Publications, Inc, Craig KD, Dobson KS.
7. Ialongo N, Edelsohn G, Werthamer-Larsson L, Crockett L, Kellams S. The significance of self-reported anxious symptoms in first-grade children. Journal of Abnormal Child Psychology 1994, 22:441-455. 10.1007/BF02168084, 7963077.
8. Lapine J-P. The epidemiology of anxiety disorders: Prevalence and societal costs. Journal of Clinical Psychiatry 2002, 63:4-8.
9. Smit F, Cuijpers P, Oostenbrink J, Batelaan N, de Graaf R, Beekman A. Costs of Nine Common Mental Disorders: Implications for Curative and Preventive Psychiatry. Journal of Mental Health Policy and Economics 2006, 9:193-200.
10. James A, Soler A, Weatherall R. Cognitive behavioural therapy for anxiety disorders in children and adolescents. Cochrane Database of Systematic Reviews 2005, CD004690.
11. Dieleman GC, Ferdinand RF. Pharmacotherapy for social phobia, generalised anxiety disorder and separation anxiety disorder in children and adolescents: an overview. Tijdschrift voor Psychiatrie 2008, 50:43-53.
12. Silverman WK, Pina AA, Viswesvaran C. Evidence-based psychosocial treatments for phobic and anxiety disorders in children and adolescents. Journal of Clinical Child & Adolescent Psychology 2008, 37:105-130.
13. Compton SN, March JS, Brent D, Albano AM, Weersing VR, Curry J. Cognitive-Behavioral Psychotherapy for Anxiety and Depressive Disorders in Children and Adolescents: An Evidence-Based Medicine Review. Journal of the American Academy of Child & Adolescent Psychiatry 2004, 43:930-959.
14. Beidel D, Albano A, Cooley-Quille M, Hibbs E, March J, Masia C, Morris T, Rabian B, Warren S. Conference on treating anxiety disorders in youth: current problems and future solutions. Anxiety Disorders Association of America; Bethesda, MD 1999,
15. Walkup JT, Albano AM, Piacentini J, Birmaher B, Compton SN, Sherrill JT, Ginsburg GS, Rynn MA, McCracken J, Waslick B, Iyengar S, March JS, Kendall PC. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. New England Journal of Medicine 2008, 359:2753-2766. 10.1056/NEJMoa0804633, 2702984, 18974308.
16. Guy W. The clinical global impression scale. The ECDEU Assessment Manual for Psychopharmacology-Revised. Volume DHEW Publ No ADM 76-338 1976, 218-222. Rockville, MD: U.S. Department of Health, Education, and Welfare Public Health Service, Alcohol, Drug Abuse, Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research.
17. RUPP Anxiety Study Group The Pediatric Anxiety Rating Scale (PARS): development and psychometric properties. Journal of the American Academy of Child & Adolescent Psychiatry 2002, 41:1061-1069. RUPP Anxiety Study Group.
18. Kendall PC. Treating anxiety disorders in children: Results of a randomized clinical trial. Journal of Consulting & Clinical Psychology 1994, 62:100-110.
19. Kendall PC, Flannery-Schroeder E, Panichelli-Mindel SM, Southam-Gerow M, Henin A, Warman M. Therapy for youths with anxiety disorders: A second randomized clinical trial. Journal of Consulting & Clinical Psychology 1997, 65:366-380.
20. Kendall PC, Hudson JL, Gosch E, Flannery-Schroeder E, Suveg C. Cognitive-behavioral therapy for anxiety disordered youth: a randomized clinical trial evaluating child and family modalities. Journal of Consulting & Clinical Psychology 2008, 76:282-297. 10.1037/0022-006X.76.2.282, 18377124.
21. Birmaher B, Axelson DA, Monk K, Kalas C, Clark DB, Ehmann M, Bridge J, Heo J, Brent DA. Fluoxetine for the treatment of childhood anxiety disorders. Journal of the American Academy of Child & Adolescent Psychiatry 2003, 42:415-423.
22. Compton SN, Grant PJ, Chrisman AK, Gammon PJ, Brown VL, March JS. Sertraline in children and adolescents with social anxiety disorder: An open trial. Journal of the American Academy of Child & Adolescent Psychiatry 2001, 40:564-571.
23. Pine DS, Walkup JT, Labellarte MJ, Riddle MA, Greenhill L, Klein R, Davies M, Sweeney M, Abikoff H, Hack S, Klee B, McCracken J, Bergman L, Piacentini J, March J, Compton S, Robinson J, O'Hara T, Baker S, Vitiello B, Ritz L, Roper M. Fluvoxamine for the treatment of anxiety disorders in children and adolescents. New England Journal of Medicine 2001, 344:1279-1285. 10.1056/NEJM200104263441703, 11323729.
24. Rynn MA, Siqueland L, Rickels K. Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. American Journal of Psychiatry 2001, 158:2008-2014. 10.1176/appi.ajp.158.12.2008, 11729017.
25. Compton SN, Burns BJ, Egger HL, Robertson E. Review of the evidence base for treatment of childhood psychopathology: Internalizing disorders. Journal of Consulting & Clinical Psychology 2002, 70:1240-1266.
26. Beidel DC, Turner SM, Sallee FR, Ammerman RT, Crosby LA, Pathak S. SET-C versus fluoxetine in the treatment of childhood social phobia. Journal of the American Academy of Child & Adolescent Psychiatry 2007, 46:1622-1632.
27. Pediatric OCD Treatment Study (POTS) Team Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. Journal of the American Medical Association 2004, 292:1969-1976. 10.1001/jama.292.16.1969, 15507582, Pediatric OCD Treatment Study (POTS) Team.
28. Kendall PC, Gosch E, Furr JM, Sood E. Flexibility within fidelity. Journal of the American Academy of Child & Adolescent Psychiatry 2008, 47:987-993.
29. Kendall PC, Safford S, Flannery-Schroeder E, Webb A. Child Anxiety Treatment: Outcomes in Adolescence and Impact on Substance Use and Depression at 7.4-Year Follow-Up. Journal of Consulting & Clinical Psychology 2004, 72:276-287.
30. Silverman WK, Pina AA, Viswesvaran C. Evidence-based psychosocial treatments for phobic and anxiety disorders in children and adolescents. Journal of Clinical Child and Adolescent Psychology 2008, 37:105-130. 10.1080/15374410701817907, 18444055.
31. Klein DF. Control groups in pharmacotherapy and psychotherapy evaluations. Treatment 1997, 1.
32. Birmaher B, Waterman GS, Ryan N, Cully M. Fluoxetine for childhood anxiety disorders. Journal of the American Academy of Child & Adolescent Psychiatry 1994, 33:993-999.
33. Black B, Uhde TW. Treatment of elective mutism with fluoxetine: A double-blind, placebo-controlled study. Journal of the American Academy of Child & Adolescent Psychiatry 1994, 33:1000-1006.
34. Mancini C, Van Ameringen M, Oakman JM, Farvolden P. Serotonergic agents in the treatment of social phobia in children and adolescents: a case series. Depression & Anxiety 1999, 10:33-39.
35. March JS, Biederman J, Wolkow R, Safferman A, Mardekian J, Cook EH, Cutler NR, Dominguez R, Ferguson J, Muller B, Riesenberg R, Rosenthal M, Sallee FR, Wagner KD. Sertraline in children and adolescents with obsessive-compulsive disorder: A multicenter randomized controlled trial. Journal of the American Medical Association 1998, 280:1752-1756. 10.1001/jama.280.20.1752, 9842950.
36. March JS, Entusah AR, Rynn M, Albano AM, Tourian KA. A randomized controlled trial of venlafaxine ER versus placebo in pediatric social anxiety disorder. Biological Psychiatry 2007, 62:1149-1154. 10.1016/j.biopsych.2007.02.025, 17553467.
37. Riddle MA, Reeve EA, Yaryura-Tobias JA, Yang HM, Claghorn JL, Gaffney G, Greist JH, Holland D, McConville BJ, Pigott T, Walkup JT. Fluvoxamine for children and adolescents with Obsessive-Compulsive Disorder: A randomized, controlled, multicenter trial. Journal of the American Academy of Child & Adolescent Psychiatry 2001, 40:222-229.
38. Suicidality in Children and Adolescents Being Treated With Antidepressant Medications. , http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm161679.htm
39. The MTA Cooperative Group A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Archives of General Psychiatry 1999, 56:1073-1086. 10.1001/archpsyc.56.12.1073, 10591283, The MTA Cooperative Group.
40. TADS Study Team Fluoxetine, Cognitive-Behavioral Therapy, and Their Combination for Adolescents With Depression: Treatment for Adolescents With Depression Study (TADS) Randomized Controlled Trial. Journal of the American Medical Association 2004, 292:807-820. 10.1001/jama.292.7.807, 15315995, TADS Study Team.
41. Brent D, Emslie G, Clarke G, Wagner KD, Asarnow JR, Keller M, Vitiello B, Ritz L, Iyengar S, Abebe K, Birmaher B, Ryan N, Kennard B, Hughes C, DeBar L, McCracken J, Strober M, Suddath R, Spirito A, Leonard H, Melhem N, Porta G, Onorato M, Zelazny J. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. Journal of the American Medical Association 2008, 299:901-913. 10.1001/jama.299.8.901, 2277341, 18314433.
42. Jureidini J, Tonkin A, Mansfield PR. TADS study raises concerns. British Medical Journal 2004, 329:133-d-1344-d.
43. Kendall PC, Compton SN, Walkup JT, Birmaher B, Albano AM, Sherrill JT, Ginsburg GS, Rynn MA, McCracken J, Gosch E, Keeton CP, Bergman L, Sakolsky D, Suveg C, Iyengar S, March JS, Piacentini J. Clinical characteristics of anxiety disorded youth. Journal of Anxiety Disorders under review.
44. Kendall PC, Hudson JL, Gosch E, Flannery-Schroeder E, Suveg C. Cognitive-behavioral therapy for anxiety disordered youth: A randomized clinical trial evaluating child and family modalities. Journal of Consulting & Clinical Psychology 2008, 76:282-297. 10.1037/0022-006X.76.2.282, 18377124.
45. Alvarez RA, Vasquez E, Mayorga CC, Feaster DJ, Mitrani VB. Increasing minority research participation through community organization outreach. Western Journal of Nursing Research 2006, 28:541-560. discussion 561-543, 10.1177/0193945906287215, 2536763, 16829637.
46. Kendall P. The C.A.T. Project Therapist Manual. 1990, Ardmore, PA: Workbook Publishing.
47. Kendall PC, Choudhury M, Hudson J, Webb A. The C.A.T. project therapist manual 2002, Ardmore, PA: Workbook Publishing.
48. March JS. Authors of TADS study reply to letter raising concerns. British Medical Journal 2005, 330:730-731. 10.1136/bmj.330.7493.730-b, 555670, 15790648.
49. Brent DA. The treatment of SSRI-resistant depression in adolescents (TORDIA): in search of the best next step. Depress Anxiety 2009, 26:871-874. 10.1002/da.20617, 19798756.
50. March JS, Vitiello B. Benefits exceed risks of newer antidepressant medications in youth-maybe. Clinical Pharmacology & Therapeutics 2009, 86:355-357.